ES2663698T3 - Procedimiento para la predicción del riesgo de progresión de tumores - Google Patents

Procedimiento para la predicción del riesgo de progresión de tumores Download PDF

Info

Publication number
ES2663698T3
ES2663698T3 ES09736808.8T ES09736808T ES2663698T3 ES 2663698 T3 ES2663698 T3 ES 2663698T3 ES 09736808 T ES09736808 T ES 09736808T ES 2663698 T3 ES2663698 T3 ES 2663698T3
Authority
ES
Spain
Prior art keywords
gene product
risk
predicting
cell proliferation
marker gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09736808.8T
Other languages
English (en)
Inventor
Peter Martin
Rüdiger Ridder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ventana Medical Systems Inc
Original Assignee
Ventana Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Medical Systems Inc filed Critical Ventana Medical Systems Inc
Application granted granted Critical
Publication of ES2663698T3 publication Critical patent/ES2663698T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Un procedimiento para predecir la posibilidad de crecimiento invasor y/o el riesgo de progresar a un cáncer de grado alto de tumores que comprende determinar en inmunohistoquímica o inmunocitoquímica la presencia simultánea de sobreexpresión del producto génico inhibidor de cinasas dependientes de ciclinas p16INK4a y la expresión de al menos un producto génico marcador de la proliferación celular en al menos una célula individual; en el que la presencia simultánea de sobreexpresión del producto génico inhibidor de cinasas dependientes de ciclinas p16INK4a y la expresión de al menos un producto génico marcador de la proliferación celular en al menos una célula individual es indicativa de una posibilidad de crecimiento invasor y un riesgo elevado de progresar a un cáncer de grado alto, y en el que el producto génico marcador de la proliferación celular se selecciona del grupo que consiste en Ki67, Ki-S2, MCM2, MCM5 y topoisomerasa 2 alfa.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11

Claims (1)

  1. imagen1
ES09736808.8T 2008-09-04 2009-09-04 Procedimiento para la predicción del riesgo de progresión de tumores Active ES2663698T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08105235 2008-09-04
EP08105235 2008-09-04
PCT/EP2009/006415 WO2010025928A1 (en) 2008-09-04 2009-09-04 Method for prediction of the progression risk of tumors

Publications (1)

Publication Number Publication Date
ES2663698T3 true ES2663698T3 (es) 2018-04-16

Family

ID=41395909

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09736808.8T Active ES2663698T3 (es) 2008-09-04 2009-09-04 Procedimiento para la predicción del riesgo de progresión de tumores

Country Status (7)

Country Link
US (3) US8728745B2 (es)
EP (1) EP2356460B1 (es)
AU (1) AU2009289822B2 (es)
CA (2) CA2735853C (es)
DK (1) DK2356460T3 (es)
ES (1) ES2663698T3 (es)
WO (1) WO2010025928A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1388734B1 (en) 2002-08-01 2004-03-03 MTM Laboratories AG Method for solution based diagnosis
EP1369694A1 (en) 2002-04-09 2003-12-10 MTM Laboratories AG Method for discrimination of metaplasias from neoplastic or preneoplastic lesions
EP1422526A1 (en) 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
EP2487253B1 (en) 2006-01-05 2015-06-24 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
EP2041574B1 (en) * 2006-07-14 2016-11-16 The Regents of The University of California Cancer biomarkers and methods of use threof
AU2008248319B2 (en) * 2007-04-30 2013-09-05 The Ohio State University Research Foundation Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
ES2627059T3 (es) 2007-08-03 2017-07-26 The Ohio State University Research Foundation Regiones ultraconservadas que codifican ARNnc
JP5723156B2 (ja) * 2007-10-11 2015-05-27 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 食道腺癌の診断及び治療のための方法及び組成物
CA2852066A1 (en) 2011-10-14 2013-04-18 The Ohio State University Methods and materials related to ovarian cancer
JP2015501843A (ja) 2011-12-13 2015-01-19 オハイオ・ステイト・イノベーション・ファウンデーション ｍｉＲ−２１およびｍｉＲ−２９ａ、エキソソーム阻害、およびがん転移に関する方法および組成物
CN104685065B (zh) 2012-01-20 2017-02-22 俄亥俄州立大学 浸润性和预后的乳腺癌生物标志物标签
EP3227687A4 (en) 2014-12-05 2018-10-24 Prelude, Inc. Dcis recurrence and invasive breast cancer
WO2016198835A1 (en) 2015-06-08 2016-12-15 Arquer Diagnostics Limited Methods and kits
ES2806498T3 (es) 2015-06-08 2021-02-17 Arquer Diagnostics Ltd Métodos para el análisis de una muestra de orina
WO2020056338A1 (en) 2018-09-14 2020-03-19 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
EP3816934A1 (en) * 2019-11-04 2021-05-05 Nathan Vinçon Method of, and computerized system for labeling an image of cells of a patient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962316A (en) 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
EP1388734B1 (en) 2002-08-01 2004-03-03 MTM Laboratories AG Method for solution based diagnosis
DE10063112A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Erhöhung der klinischen Spezifität bei der Detektion von Tumoren und ihren Vorstufen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
EP1369694A1 (en) 2002-04-09 2003-12-10 MTM Laboratories AG Method for discrimination of metaplasias from neoplastic or preneoplastic lesions
EP1507148B1 (en) 2003-08-25 2005-02-23 MTM Laboratories AG Method for detecting carcinomas in a solubilized cervical body sample
EP1422526A1 (en) * 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
EP1510820B1 (en) 2003-08-25 2010-03-17 MTM Laboratories AG Method for detecting medically relevant conditions in a solubilized LBC sample

Also Published As

Publication number Publication date
US20150099651A1 (en) 2015-04-09
US20110183333A1 (en) 2011-07-28
WO2010025928A1 (en) 2010-03-11
US8728745B2 (en) 2014-05-20
CA3117744C (en) 2022-07-19
EP2356460A1 (en) 2011-08-17
AU2009289822A1 (en) 2010-03-11
EP2356460B1 (en) 2018-01-24
AU2009289822B2 (en) 2015-04-30
CA3117744A1 (en) 2010-03-11
DK2356460T3 (en) 2018-03-26
CA2735853A1 (en) 2010-03-11
US20230133528A1 (en) 2023-05-04
CA2735853C (en) 2021-08-31

Similar Documents

Publication Publication Date Title
ES2663698T3 (es) Procedimiento para la predicción del riesgo de progresión de tumores
CL2012003680A1 (es) Compuestos derivados de (1,8) naftiridinas 2,4 diaril sustituidas inhibidores de quinasas; su procedimiento de obtencion; composicion farmaceutica; y su uso para el tratamiento y/o prevencion de cancer, tumor, tumores malignos, entre otros; kit farmaceutico.
Kasajima et al. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours
CL2008000020A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos.
HK1143190A1 (en) Gene expression markers of tumor resistance to her2 inhibitor treatment
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
CL2009000040A1 (es) Uso del compuesto 2,2-dimetil-n-((s)-6-oxo-6,7-dihidro-5h-dibenzo[b,d]azepin-7-il)-n'-(2,2,3,3,3-pentafluor-propil)-malonamida para el tratamiento del cancer, en particular de tumores solidos, metodos de fabricacion y kit que lo contiene.
AR064458A1 (es) Antagonistas especificos de vegf para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadios tempranos
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
CL2007001624A1 (es) Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular.
BR112015009752A2 (pt) conjugados de anticorpo/fármaco e métodos de uso
EA201270606A1 (ru) Новое противоопухолевое применение кабазитаксела
WO2006039582A3 (en) Compositions and methods for diagnosing and treating brain cancer and identifying neural stem cells
CL2008003200A1 (es) Compuestos derivados de tiazol, inhibidores de la proteina quinasas; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de vejiga, de mama y de rinon.
WO2008094964A3 (en) Cancer therapy prognosis
ES2570631T3 (es) Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal
WO2012154567A3 (en) Human invasion signature for prognosis of metastatic risk
Lai et al. DEPTOR expression negatively correlates with mTORC1 activity and tumor progression in colorectal cancer
BR112015012507A8 (pt) método in vitro de seleção de um indivíduo diagnosticado ou suspeito de ter câncer e uso de um inibidor de telomerase
UY36200A (es) Conjunto de biomarcadores específicos para diagnóstico no invasivo de cáncer de hígado
WO2012109632A3 (en) Crown-like structures as a biomarker for cancer risk and cancer prognosis
AR026037A1 (es) Indolinonas sustituidas en posicion 5, su preparacion y su utilizacion como medicamentos
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
ES2482168T3 (es) Uso de opioides del grupo de la metadona para el tratamiento de pacientes con cáncer resistente
HK1126278A1 (en) Identification of non-small cell lung carcinoma (nsclc) tumors expressing pdgfr-alpha pdgfr(nsclc)